ABSTRACT

Chemo-radiotherapy patients almost always have an inflammatory response of the epithelial mucosa as a result of the cytotoxic effects, which causes mucositis. Mucositis develops in approximately 40% of chemotherapy patients and approximately 90% of head and neck cancer (HNC) patients treated with both chemo-radiotherapy. Patients with high-grade mucositis will be hospitalized around 19% of the time, lowering quality of life, resulting in a poor prognosis, and incurring ongoing treatment costs. Several therapies and prevention guidelines are currently available, but their effectiveness rates are unknown. This analysis shows mucositis completely, analyzing the effect of standard chemo- radiotherapy and tailored therapy on mucositis progression and pointing out the limitations and benefits of current mucositis treatment approaches and evaluation guidelines. Furthermore, an examination of the research to determine the existing biomarkers to predict patient risk of developing oral mucositis and their relevance in early diagnosis. Although the expression levels of some proteins involved in the inflammatory response, such as TNF- or IL-1, are associated with the mucositis process, their presence does not rule out other mucositis-free inflammation events. This strongly suggests the necessity to identify biomarkers that expressly incorporate mucositis as a measure of progression. Non-coding RNAs may have this capability. Keywords: Oral mucositis, HNC, Biomarker, Cytokine, Non-coding RNA, Quality of life
Publication date: 15/12/2023

https://ijbpas.com/pdf/2023/December/MS_IJBPAS_2023_DECEMBER_SPCL_1083.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.12.1083